Deciphera Pharmaceuticals announced a restructuring with the intention of prioritizing clinical development of specific programs and streamlining the Waltham, Mass.-based company’s commercial operations. In addition to cutting one of its programs, Deciphera plans to reduce about 140 positions.
If you are not happy with the results below please do another search
50 search results for:
The head of the World Health Organization (WHO) voiced concern on November 30 that some countries were introducing blanket measures against the Omicron coronavirus variant that may not be necessary and penalized African nations unfairly.
White House Press Secretary Jen Psaki said on November 30 the Biden administration is continuing to work on building a consensus toward waving intellectual property rights tied to Covid-19 vaccines.
BioNTech and Pfizer’s COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech’s Chief Executive told Reuters, as the firm weighs the need to upgrade its commonly used shot.
The U.S. Food and Drug Administration said on November 30 the regulatory agency was evaluating the effectiveness of authorized Covid-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
One day after Bay Area-based Olema Pharmaceuticals announced that falsified information regarding its Phase I/II breast cancer data was circulating across the Internet, the company released topline data for OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN).
The Centers for Disease Control and Prevention (CDC) shifted its recommendation on adults getting a booster Covid-19 vaccine to now include everyone ages 18 years and older as the threat of the new Omicron variant looms.
Merck & Co. Inc.’s experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on NOvember 30.
GSK hired one of the scientists behind Pfizer’s mRNA COVID-19 shot, Phil Dormitzer, as the company’s global head of R&D for vaccines and he will join the British drugmaker from Dec. 3.
The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.